CPT® Code 0628T

Official Description

Percutaneous injection of allogeneic cellular and/or tissue-based product, intervertebral disc, unilateral or bilateral injection, with fluoroscopic guidance, lumbar; each additional level (List separately in addition to code for primary procedure)

Common Language Description

The CPT® Code 0628T refers to a specific medical procedure involving the percutaneous injection of allogeneic cellular and/or tissue-based products into the intervertebral disc. Allogeneic cells, often referred to as universal cells, are derived from a single source, such as umbilical cord blood, and are stored in a master cell bank. These cells are processed for specific therapeutic applications, particularly in the treatment of intervertebral disc degeneration. The procedure is designed to provide pain relief and improve the quality of the disc without the need for invasive surgical interventions. This method is considered more convenient compared to autologous cell therapy, which involves using the patient's own cells. During the procedure, local anesthesia is administered, and fluoroscopic guidance is utilized to ensure accurate placement of the injection. The injection consists of a ready-to-use material containing a predetermined number of cells per segment being treated. It is important to note that this code is used to report injections at each additional level beyond the primary procedure, which is reported separately using the appropriate codes for the first level of injection.

1. Indications

The procedure described by CPT® Code 0628T is indicated for the treatment of intervertebral disc degeneration. This condition may present with symptoms such as chronic back pain, reduced mobility, and discomfort that can significantly impact a patient's quality of life. The use of allogeneic cellular and/or tissue-based products aims to alleviate these symptoms and enhance the overall health of the intervertebral disc.

Intervertebral Disc Degeneration This condition involves the deterioration of the discs that act as cushions between the vertebrae in the spine, leading to pain and reduced function.

2. Procedure

The procedure involves several key steps to ensure effective delivery of the allogeneic cellular product into the intervertebral disc.

Step 1: Preparation The patient is positioned appropriately, and local anesthesia is administered to minimize discomfort during the injection. The area of injection is then sterilized to reduce the risk of infection.
Step 2: Imaging Guidance Fluoroscopic guidance is employed to visualize the intervertebral disc and ensure accurate placement of the injection. This imaging technique allows the physician to navigate to the correct anatomical location with precision.
Step 3: Injection A ready-to-use material containing allogeneic cells is prepared for injection. The physician carefully injects this material into the intervertebral disc, targeting the specific segment that requires treatment. The number of cells injected is predetermined based on the treatment protocol.
Step 4: Post-Injection Monitoring After the injection, the patient is monitored for any immediate adverse reactions and to assess the effectiveness of the procedure. Instructions for post-procedure care are provided to ensure optimal recovery.

3. Post-Procedure

Following the procedure, patients may experience some discomfort at the injection site, which is typically managed with standard pain relief measures. It is essential for patients to follow any specific post-procedure instructions provided by their healthcare provider, which may include activity restrictions and follow-up appointments to monitor the treatment's effectiveness. Recovery time can vary, but many patients can resume normal activities relatively quickly, depending on their individual response to the procedure.

Short Descr	PERQ NJX ALGC FLUOR LMBR EA
Medium Descr	PERQ NJX ALGC CELL &/PRDCT UNI/BI FLUOR LMBR EA
Long Descr	Percutaneous injection of allogeneic cellular and/or tissue-based product, intervertebral disc, unilateral or bilateral injection, with fluoroscopic guidance, lumbar; each additional level (List separately in addition to code for primary procedure)
Status Code	Carriers Price the Code
Global Days	ZZZ - Code Related to Another Service
PC/TC Indicator (26, TC)	0 - Physician Service Code
Multiple Procedures (51)	0 - No payment adjustment rules for multiple procedures apply.
Bilateral Surgery (50)	2 - 150% payment adjustment does NOT apply.
Physician Supervisions	09 - Concept does not apply.
Assistant Surgeon (80, 82)	0 - Payment restriction for assistants at surgery applies to this procedure...
Co-Surgeons (62)	0 - Co-surgeons not permitted for this procedure.
Team Surgery (66)	0 - Team surgeons not permitted for this procedure.
Diagnostic Imaging Family	99 - Concept Does Not Apply
APC Status Indicator	Items and Services Packaged into APC Rates
ASC Payment Indicator	Packaged service/item; no separate payment made.
Berenson-Eggers TOS (BETOS)	none
MUE	4

This is an add-on code that must be used in conjunction with one of these primary codes.

0627T

MPFS Status: Carrier Priced APC J1 ASC J8 Percutaneous injection of allogeneic cellular and/or tissue-based product, intervertebral disc, unilateral or bilateral injection, with fluoroscopic guidance, lumbar; first level